L Review of Operations by Therapeutic Area * In this section, all figures for sales and year-on-year changes are based on J-GAAP.  Ur ology W ith V esicare and mirabegron, Astellas aims to reinforce its overactive bladder (OAB) franchise. Urology is a therapeutic area in which Astellas has already  established its status as a Global Category Leader (GCL).  Through sales of Harnal, Vesicare and mirabegron  (generic name), we command a strong presence in the  market for drugs used to treat the conditions of benign  prostatic hyperplasia (BPH) and OAB. on promoting sales of mirabegron, which is marketed  under the brand names of Myrbetriq in the U.S.; BETMIGA  in EMEA, Asia & Oceania; and Betanis in Japan. The  product is currently available in over 25 countries around  the world. Our OAB franchise expanded steadily due to the  growth of Vesicare and a contribution from mirabegron. In  fiscal 2013, aggregate sales of these two OAB treatments  grew 40% year on year to ¥163.9 billion. On a regional  basis, we recorded double-digit sales growth in Japan,  EMEA, the Americas and Asia & Oceania. Sales of Harnal fell in Japan and EMEA, reflecting   erosion by generic competition. In contrast, sales of  Harnal continued to increase in Asia & Oceania. We are working to maintain Astellas’ GCL status in  urology by introducing a stream of new products. We  gained regulatory approval in Europe for VESOMNI, a  combination drug of Vesicare and Harnal, in May 2013,  and launched it in September 2013. We are also advanc- ing several projects in various stages of clinical develop- ment, including EB178 (a combination therapy comprising  solifenacin and mirabegron). Currently in Phase 3 trials,  EB178 is an important development program in our  efforts to reinforce the OAB franchise. Anticholinergics such as Vesicare are still the standard  therapy for OAB. Mirabegron, which is a beta-3 adrenergic  receptor agonist, has a different mechanism of action.  Since its launch in Japan in 2011, it has become a well- established new treatment option for OAB patients. We  plan to strengthen our OAB franchise further by focusing  Review of Operations  Vesicare   Mirabegron (¥ billion) 0 200 150 100 50 177.0 120.7 56.4 162.0 133.8 28.2 163.9 135.7 28.2 116.9 110.0 6.9 2013.3 2014.3 2015.3  (Forecasts) IFRS J-GAAP +40% +9%  Japan   Americas   EMEA   Asia & Oceania (¥ billion) 0 200 150 100 50 116.9 30.1 48.4 35.1 3.0 163.9 44.7 72.6 42.3 3.8 162.0 42.8 72.6 42.3 3.8 177.0 52.2 74.1 45.1 5.1 2013.3 2014.3 2015.3  (Forecasts) IFRS J-GAAP +40% +9% Total Sales of Vesicare and Mirabegron (By Region)  Total Sales of Vesicare and Mirabegron (By Product)  Annual Report 2014 _  Astellas Pharma Inc.  41